Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DMR-001 · 1 trial · 1 indication
Incidence and severity of AEs and SAEs, including DLTs and AEs resulting in dose modification (interruption, reduction, or discontinuation)
| Arm | Type | Description |
|---|---|---|
| Part 1: DMR-001 monotherapy dose escalation phase. | EXPERIMENTAL | DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the protocol defined starting dose and dosing schedule to identify the maximum tolerated dose and/or recommended dose(s) for expansion. |
| Part 2: DMR-001 monotherapy dose expansion phase. | EXPERIMENTAL | DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined recommended dose(s) for expansion based on Part 1. |
| Part 3: DMR-001 and ruxolitinib combination dose escalation followed by dose expansion. | EXPERIMENTAL | DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined dose and regimen, but in combination with an oral tablet of ruxolitinib, a standard of care drug approved therapy for the treatment of MF. |
| Name | Type | Description |
|---|---|---|
| DMR-001 | DRUG | DMR-001 will be administered at protocol defined dose at a frequency of every 4 weeks. |
| Ruxolitinib | DRUG | Ruxolitinib will be administered according to Prescribing Information/SmPC. |
Inclusion Criteria: * Signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and the protocol. * Diagnosis/confirmation of ET or MF as defined in the protocol. * Documented CALR exon-9 mutation. * Willingness to undergo bone marrow biopsy and asp...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, IMGN632, ABBV-744 |
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Luspatercept, BMS-986158, Fedratinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics Inc | KPTIQ | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Axatilimab, Ruxolitinib, INCB160058, INCB057643, INCA033989 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Revumenib |
DMR-001 is an investigational small molecule developed by Damora Therapeutics, Inc. for myeloproliferative neoplasms (MPNs). It is designed to target mutCALR, a mutant form of the calreticulin protein, and is being studied in biomarker-selected patients whose disease carries that mutation. DMR-001 is in Phase 1 clinical development.
DMR-001 targets mutCALR, the mutant form of the calreticulin protein found in a subset of myeloproliferative neoplasms. By binding this mutant protein target, DMR-001 is intended to act on the disease-driving abnormality specific to CALR-mutant MPN patients, which is why the clinical program enrolls only biomarker-selected participants.
DMR-001 is being developed by Damora Therapeutics, Inc., a biopharmaceutical company whose common stock trades under the ticker DMRA. Damora is the sponsor of the Phase 1 study evaluating DMR-001 in CALR-mutant myeloproliferative neoplasms in the United States and Australia.
DMR-001 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 program consists of one active, recruiting study in CALR-mutant myeloproliferative neoplasms, with no completed trials reported to date.
DMR-001 is being evaluated in trial NCT07849231, titled A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms. The Phase 1 study is currently recruiting, plans to enroll 250 participants aged 18 years and older of all sexes, and is running in the United States and Australia.
The DMR-001 Phase 1 study NCT07849231 is a controlled trial but is not randomized and is not double-blind. It enrolls only biomarker-selected participants with CALR-mutant myeloproliferative neoplasms, does not include healthy volunteers, and is recruiting at sites in the United States and Australia with a planned enrollment of 250.